Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 327

Sort by

Sort Order Select

Journal Articles

Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

Blood (2019) 134 (Supplement_1): 743.

https://doi.org/10.1182/blood-2019-123382

Published: 2019

Journal Articles

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Christopher J. Walker, PhD, Ann-Kathrin Eisfeld, MD, Hatice G Ozer, PhD, Jessica Kohlschmidt, PhD, Deedra Nicolet, Krzysztof Mrózek, MD PhD, Dimitrios Papaioannou, MD, Luke K Genutis, BS, Bayard L Powell, MD, Geoffrey L. Uy, MD, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Richard Stone, MD, Ramiro Garzon, MD, John C. Byrd, MD, Albert de la Chapelle, MD PhD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 1247.

https://doi.org/10.1182/blood-2019-127478

Published: 2019

Journal Articles

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Alex G Sieg, MD MS, Christopher Strouse, MD, Sarah L Mott, Joshua Reeder, Sergei Syrbu, MD PhD, Guohua An, MD PhD, Grerk Sutamtewagul, MD, Brian K. Link, MD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 1626.

https://doi.org/10.1182/blood-2019-127349

Published: 2019

Journal Articles

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Brian J Ball, Meier Hsu, MS, Sean M. Devlin, PhD, Christopher Famulare, MS, Sheng F Cai, MDPhD, Andrew Dunbar, MD, Zachary D. Epstein-Peterson, MD, Kamal Menghrajani, MD, Jacob L Glass, MDPhD, Justin Taylor, MD, Aaron D Viny, MDMS, Aaron D Goldberg, MDPhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 18.

https://doi.org/10.1182/blood-2019-125319

Published: 2019

Journal Articles

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Bhaskar Kolla, MBBS, Nurul Aidah Abdul Halim, MBBS, Zohar Sachs, MD PhD, Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Fiona He, MD, Lao Zhentang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 3432.

https://doi.org/10.1182/blood-2019-123306

Published: 2019

Journal Articles

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Dimitrios Papaioannou, MD, Deedra Nicolet, MS, Kellie J Archer, PhD, Allison Walker, Krzysztof Mrózek, MD PhD, Andrew J. Carroll, PhD, Jessica Kohlschmidt, PhD, Ann-Kathrin Eisfeld, MD, Marius Bill, MD PhD, Christopher J. Walker, PhD, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard Stone, MD, John C. Byrd, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2694.

https://doi.org/10.1182/blood-2019-125727

Published: 2019

Journal Articles

Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR

Matthew J. Wieduwilt, MD PhD, Wendy Stock, MD, Anjali S. Advani, MD, Selina M. Luger, MD FRCPC, Richard A. Larson, MD, Martin S. Tallman, MD, Frederick R. Appelbaum, MD, Mei-Jie Zhang, Khalid Bo-Subait, Brenda M. Sandmaier, MD, Marcos de Lima, MD, Partow Kebriaei, MD, Mark Litzow, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD

Blood (2019) 134 (Supplement_1): 261.

https://doi.org/10.1182/blood-2019-128560

Published: 2019

Journal Articles

Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leukemia Group B (CALGB)/Alliance Protocols

Marius Bill, MD PhD, Krzysztof Mrózek, MD PhD, Jessica Kohlschmidt, PhD, Deedra Nicolet, MS, Brian Giacopelli, BS, Christopher J. Walker, PhD, Dimitrios Papaioannou, MD, Ann-Kathrin Eisfeld, MD, Jonathan E. Kolitz, MD, Bayard L Powell, MD, Andrew J. Carroll, PhD, Richard M. Stone, MD, John C. Byrd, MD, Ramiro Garzon, MD, Christopher C. Oakes, PhD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 182.

https://doi.org/10.1182/blood-2019-128623

Published: 2019

Journal Articles

The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Andrew M. Evens, DO, MSc, Alexey Danilov, MD PhD, Deepa Jagadeesh, MDMPH, Amy Sperling, BS, Seo-Hyun Kim, MD, Ryan Vaca, MD, Catherine Wei, MD MA, Daniel Rector, Suchitra Sundaram, MD, Nishitha Reddy, MD, Yong Lin, PhD, Umar Farooq, MD, Christopher D'Angelo, MD, David A. Bond, MD, Stephanie Berg, DO, Michael C. Churnetski, Amandeep Godara, MD, Nadia Khan, MD, Yun Kyong Choi, MD, Maryam Yazdy, MD, Emma Rabinovich, MD, Gaurav Varma, MD MSPH, Reem Karmali, MD, Agrima Mian, MBBS, MD, Jeremy Ramdial, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Albert Ren, Ayushi Chauhan, MBBS, Catherine Diefenbach, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Scott E. Smith, MD PhD, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Vaishalee P. Kenkre, MD, Adam Zayac, MD, Seth M Maliske, MD, Narendranath Epperla, MDMS, Parameswaran Venugopal, MD, Tatyana A. Feldman, MD, Stephen D. Smith, MD, Andrzej Stadnik, MPH, BS, Izidore S. Lossos, MD, Kevin A. David, MD, Seema Naik, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Adam J Olszewski, MD, Juan Pablo Alderuccio, MD

Blood (2019) 134 (Supplement_1): 397.

https://doi.org/10.1182/blood-2019-122971

Published: 2019

Journal Articles

Pediatric-Inspired Regimens Are Associated with Better Outcomes When Compared with Hypercvad in Hispanic Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Roberta Demichelis, MD, Karla Adriana Espinosa, MD MSc, Juan Rangel-Patiño, MD, Emmanuel Almanza, MD, Ana Cooke, MD

Blood (2019) 134 (Supplement_1): 3877.

https://doi.org/10.1182/blood-2019-125370

Published: 2019

Journal Articles

Individualized, Low Dose, Fixed Duration Lenalidomide Maintenance Is an Effective Strategy in High MRD Disease Post Chemo-Immunotherapy in CLL: Outcomes of a Randomized Controlled Trial

Nishant Jindal, MD MBBS, Man Updesh Singh Sachdeva, MD, Arihant Jain, MD DM, Gaurav Prakash, MD DM, Alka Khadwal, MD, Sreejesh Sreedharanunni, DM, Neelam Varma, MD, Pankaj Malhotra, MD, Deepesh Lad, MD DM

Blood (2019) 134 (Supplement_1): 5471.

https://doi.org/10.1182/blood-2019-127065

Published: 2019

Journal Articles

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment

Ann-Kathrin Eisfeld, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MD PhD, Deedra Nicolet, MS, Alice S. Mims, MD, Dimitrios Papaioannou, MD, Christopher J. Walker, PhD, James S. Blachly, MD, Sophia E. Maharry, Andrew J. Carroll, PhD, Richard M. Stone, MD, Bayard L Powell, MD, Albert de la Chapelle, MD PhD, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, John C. Byrd, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2681.

https://doi.org/10.1182/blood-2019-130076

Published: 2019

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD PhD MPH, Hong Li, Brian P. Hobbs, PhD, Aaron T. Gerds, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Samjhana Bogati, RN, Eric Parsons, RN, Benjamin Pannell, Matt Kalaycio, MD, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 2595.

https://doi.org/10.1182/blood-2019-132178

Published: 2019

Journal Articles

A Modified CALGB-10403 in Hispanic Adolescent and Young Adults with Philadelphia -Negative Acute Lymphoblastic Leukemia: Promising Results Despite a High-Rate of Metabolic and Hepatic Toxicities

Juan Rangel-Patiño, MD, Alvaro Cabrero Garcia, Carolina Balderas-Delgado, MD, Lauro Fabian Amador, MD, Yvette Neme Yunes, Ana Cooke, MD, Adriana Rosas, Roberta Demichelis, MD

Blood (2019) 134 (Supplement_1): 1352.

https://doi.org/10.1182/blood-2019-126108

Published: 2019

Journal Articles

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Carlyn Rose Tan, MD, Stefan K. Barta, MD MRCP, MS, Shelly Y. Lensing, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1595.

https://doi.org/10.1182/blood-2019-129702

Published: 2019

Journal Articles

Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood . 2019;133(14):1548-1559.

Blood (2019) 134 (13): 1111.

https://doi.org/10.1182/blood.2019002613

Published: 2019

Journal Articles

Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

Kathryn Lurain, MD MPH, Thomas S. Uldrick, MD MS, Priscila H. Goncalves, MD, Ramya Ramaswami, MBBS, MPH, Mark N. Polizzotto, Anaida Widell, Seth M. Steinberg, PhD, Elaine S. Jaffe, Stefania Pittaluga, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Richard F. Little, MD MPH, Robert Yarchoan, MD

Blood (2018) 132 (Supplement 1): 2963.

https://doi.org/10.1182/blood-2018-99-112169

Published: 2018

Journal Articles

Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

Matthew J Maurer, MS, Amy S. Ruppert, MAS, PhD, Brian K. Link, MD, Lawrence D Kaplan, MD, David J Inwards, MD, Andrew L. Feldman, MD, Eric D. Hsi, MD, Adam Pettinger, Jonathon B. Cohen, MD MS, Peter Martin, FRCPC, MD MS, Brad S Kahl, MD, Nancy L. Bartlett, MD, James R. Cerhan, MD PhD, John P. Leonard, MD, Thomas M. Habermann, MD

Blood (2018) 132 (Supplement 1): 2878.

https://doi.org/10.1182/blood-2018-99-110558

Published: 2018

Journal Articles

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/ BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701

Matthew J. Wieduwilt, MD PhD, Jun Yin, PhD, Meir Wetzler, MD, Geoffrey L. Uy, MD, Bayard L. Powell, MD, Jonathan E. Kolitz, MD, Michaela Liedtke, MD, Wendy Stock, MD, Jan H Beumer, Ryan J. Mattison, MD, Elizabeth Storrick, Steven Devine, Scott E. Smith, MD PhD, Richard M. Stone, MD, Richard A. Larson, MD

Blood (2018) 132 (Supplement 1): 309.

https://doi.org/10.1182/blood-2018-99-120029

Published: 2018

Journal Articles

Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial

Eytan M. Stein, MD, Abigail Shoben, Uma Borate, MD, Maria R. Baer, MD, Wendy Stock, MD, Prapti A. Patel, MD, Tibor Kovacsovics, MD, William Blum, MD, Jo-Anne Vergilio, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, Sonja Marcus, MPH, Mona Stefanos, MBChB, Jordan Chervin, Brian J. Druker, MD, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 287.

https://doi.org/10.1182/blood-2018-99-118287

Published: 2018

NARROW

Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Algorithm in Patients (Pts) Treated on Cancer and Leukemia Group B (CALGB)/Alliance Protocols

The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Pediatric-Inspired Regimens Are Associated with Better Outcomes When Compared with Hypercvad in Hispanic Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Individualized, Low Dose, Fixed Duration Lenalidomide Maintenance Is an Effective Strategy in High MRD Disease Post Chemo-Immunotherapy in CLL: Outcomes of a Randomized Controlled Trial

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

A Modified CALGB-10403 in Hispanic Adolescent and Young Adults with Philadelphia -Negative Acute Lymphoblastic Leukemia: Promising Results Despite a High-Rate of Metabolic and Hepatic Toxicities

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood . 2019;133(14):1548-1559.

Radiation-Sparing Treatment of HIV-Related Primary Central Nervous System Lymphoma with Antiretroviral Therapy, Rituximab and High-Dose Methotrexate

Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/ BCR-ABL1 -Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Final Results of Alliance/CALGB Study 10701

Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only